GPR35; | |
TDP1; CTDSP1; RECQL; BLM; HSD17B1; AKR1B1; HSD17B2; HSD17B10; HPGD; ALOX15; NOX4; USP2; APEX1; POLB; | |
DUSP3; | |
GAA; BCHE; | |
FLT4; TEK; PDGFRB; INSR; DAPK1; AKT1; MET; PLK4; FLT3; IGF1R; CSNK2A1; ERBB2; EGFR; AURKB; NUAK1; EPHB4; AURKA; PLK1; KDR; GSK3B; SRC; MAP3K8; BRAF; PTK2; | |
CA2; CA13; CA12; CA9; CA5A; CA14; CA7; CA4; CA6; | |
AR; | |
ESRRA; | |
ALOX5; TYR; XDH; | |
KDM4E; | |
BACE1; | |
HIF1A; TP53; AHR; | |
SLC22A6; SLCO1B3; SLCO1B1; | |
ABCG2; ABCC1; | |
HBB; SMAD3; LMNA; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.089E-12 | 5.646E-10 | CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.541E-12 | 2.831E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HBB, NOX4 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.631E-10 | 4.552E-08 | ABCC1, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, SLCO1B1, SLCO1B3, TEK |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.047E-10 | 5.503E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.841E-10 | 1.659E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HBB, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.817E-09 | 3.698E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HBB, NOX4, SRC |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.299E-09 | 6.193E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 8.290E-09 | 1.389E-06 | EGFR, ERBB2, INSR, MET, NOX4, PDGFRB, PTK2, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.598E-08 | 2.434E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.747E-08 | 3.987E-06 | EGFR, ERBB2, INSR, KDR |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.867E-08 | 4.134E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 4.352E-08 | 5.998E-06 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 7.856E-08 | 1.030E-05 | ALOX15, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.069E-07 | 1.362E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.089E-07 | 1.378E-05 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 2.234E-07 | 2.630E-05 | AKR1B1, AKT1, APEX1, CYP1B1, EGFR, SRC, TP53 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.335E-07 | 2.704E-05 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 2.923E-07 | 3.332E-05 | FLT3, FLT4, KDR, PDGFRB |
MF | GO:0005488; binding | GO:0019901; protein kinase binding | 3.659E-07 | 4.107E-05 | AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, HIF1A, PDGFRB, PLK1, PTK2, SMAD3, SRC, TP53 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 5.198E-07 | 5.441E-05 | AKR1B1, AKT1, BCHE, EGFR, HSD17B2, KDR, PDGFRB, SLC22A6, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 5.536E-07 | 5.713E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 5.766E-07 | 5.923E-05 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3, TP53 |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.161E-06 | 1.080E-04 | ALOX15, ALOX5, HPGD |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.259E-06 | 1.156E-04 | CYP1A1, PDGFRB, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.591E-06 | 1.420E-04 | AKR1B1, AKT1, APEX1, GSK3B, IGF1R, INSR, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.607E-06 | 1.428E-04 | AKR1B1, APEX1, BLM, BRAF, CYP1B1, EGFR, KDR, SRC, TP53 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.851E-06 | 1.610E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.026E-06 | 1.737E-04 | BCHE, CYP1A2, CYP3A4 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 2.026E-06 | 1.737E-04 | FLT3, FLT4, KDR |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 3.208E-06 | 2.521E-04 | AKT1, AR, DAPK1, HSPA1A, LMNA, SRC |
BP | GO:0032502; developmental process | GO:0007568; aging | 3.472E-06 | 2.690E-04 | AKT1, APEX1, AURKB, CYP1A1, NOX4, PDGFRB, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:0042542; response to hydrogen peroxide | 4.227E-06 | 3.163E-04 | AKR1B1, APEX1, CYP1B1, HBB, PDGFRB, SRC |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 4.834E-06 | 3.580E-04 | BLM, RECQL, TP53 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 5.958E-06 | 4.282E-04 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1, TP53 |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 6.115E-06 | 4.380E-04 | FLT3, KDR, PDGFRB, PTK2, TEK |
MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 7.056E-06 | 4.988E-04 | AKT1, EGFR, ERBB2, FLT4, MET, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 7.319E-06 | 5.092E-04 | EPHB4, GAA, INSR, PTK2 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.319E-06 | 5.092E-04 | AHR, CSNK2A1, HIF1A, KDR |
BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 7.392E-06 | 5.126E-04 | CYP1B1, EPHB4, FLT4, HIF1A, KDR, PDGFRB, PTK2, TEK |
MF | GO:0005488; binding | GO:0002039; p53 binding | 8.181E-06 | 5.655E-04 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 1.226E-05 | 8.139E-04 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.255E-05 | 8.308E-04 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 1.324E-05 | 8.738E-04 | AKT1, CA2, PDGFRB, SRC |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.528E-05 | 9.960E-04 | APEX1, POLB |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.550E-05 | 1.008E-03 | AR, BLM, CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9, ESRRA, SMAD3, TP53 |
BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1.675E-05 | 1.076E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.675E-05 | 1.076E-03 | AKR1B1, AKT1, AR, EGFR, SRC |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.778E-05 | 1.125E-03 | BCHE, CYP1A1, EGFR, TP53, TYR |
BP | Unclassified; | GO:0006461; protein complex assembly | 1.942E-05 | 1.215E-03 | AR, BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, PTK2, SLC22A6, SMAD3, SRC, TEK, TP53 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 2.118E-05 | 1.318E-03 | AR, EGFR, HSD17B1, IGF1R, INSR |
BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 2.242E-05 | 1.383E-03 | AKT1, FLT4, HIF1A, KDR, TEK |
BP | GO:0009987; cellular process | GO:0051259; protein oligomerization | 2.340E-05 | 1.436E-03 | AR, BLM, BRAF, HBB, HSD17B10, IGF1R, INSR, SLC22A6, TEK, TP53 |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.457E-05 | 1.494E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, NOX4, PDGFRB, SMAD3, SRC, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.159E-05 | 1.869E-03 | ALOX15, ALOX5, HPGD |
BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 3.816E-05 | 2.228E-03 | APEX1, BRAF, NOX4, TEK, TYR |
BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 3.846E-05 | 2.237E-03 | AURKA, GSK3B, HSPA1A, MET, PLK1, PLK4 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 3.852E-05 | 2.237E-03 | ABCG2, AHR, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3 |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 4.332E-05 | 2.483E-03 | AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, NOX4, SRC, TYR, USP2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.572E-05 | 2.599E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.572E-05 | 2.599E-03 | CYP1A1, CYP3A4 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.238E-05 | 2.955E-03 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKA, AURKB, BLM, CSNK2A1, CTDSP1, DUSP3, ESRRA, GSK3B, HIF1A, HPGD, HSPA1A, LMNA, NUAK1, PLK1, POLB, RECQL, SMAD3, SRC, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.602E-05 | 3.104E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 5.598E-05 | 3.104E-03 | AURKA, AURKB, PLK1, POLB |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 8.542E-05 | 4.551E-03 | HIF1A, SMAD3, TP53 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 8.641E-05 | 4.585E-03 | AKR1B1, APEX1, BLM, GAA, HIF1A, NOX4, SRC |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 9.120E-05 | 4.774E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 9.419E-05 | 4.884E-03 | AHR, AR, GSK3B, SMAD3, TP53 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.795E-05 | 5.019E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.094E-04 | 5.539E-03 | AKT1, AR, BRAF, CA2, CTDSP1, CYP1B1, EGFR, ERBB2, ESRRA, GSK3B, HIF1A, INSR, KDR, PDGFRB, PTK2, SMAD3, SRC, TEK, XDH |
BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 1.106E-04 | 5.586E-03 | AKR1B1, APEX1, CYP1B1, KDR, TP53 |
MF | GO:0005215; transporter activity | GO:0015347; sodium-independent organic anion transmembrane transporter activity | 1.116E-04 | 5.601E-03 | SLC22A6, SLCO1B1, SLCO1B3 |
BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 1.176E-04 | 5.858E-03 | AURKB, NOX4, PDGFRB, SRC |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 1.290E-04 | 6.386E-03 | CYP1A2, EGFR, ESRRA, HPGD, PDGFRB |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.326E-04 | 6.546E-03 | EGFR, ERBB2, MET, PDGFRB |
MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 1.406E-04 | 6.894E-03 | APEX1, BLM, POLB, TP53 |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.419E-04 | 6.915E-03 | AHR, AURKA, BRAF, EGFR, ERBB2, HIF1A, SMAD3, TP53, TYR |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.516E-04 | 7.161E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.516E-04 | 7.161E-03 | BLM, RECQL |
CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.516E-04 | 7.161E-03 | AURKA, AURKB |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.538E-04 | 7.248E-03 | BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.600E-04 | 7.447E-03 | CYP1B1, FLT4, HIF1A |
BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1.607E-04 | 7.447E-03 | AKT1, CSNK2A1, DAPK1, SMAD3, SRC, XDH |
BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 1.611E-04 | 7.447E-03 | AKT1, EGFR, PLK1, SMAD3, SRC |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.725E-04 | 7.940E-03 | AHR, AKR1B1, AKT1, ALOX15, ALOX5, AR, AURKA, AURKB, BLM, BRAF, CA13, CA2, CA7, CSNK2A1, DUSP3, EPHB4, ERBB2, FLT3, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, LMNA, MAP3K8, PLK1, PLK4, PTK2, SMAD3, SRC, TP53, TYR, XDH |
BP | GO:0051179; localization | GO:0043252; sodium-independent organic anion transport | 1.786E-04 | 8.172E-03 | SLC22A6, SLCO1B1, SLCO1B3 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.859E-04 | 8.468E-03 | FLT4, KDR, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0010605; negative regulation of macromolecule metabolic process | 1.907E-04 | 8.653E-03 | AHR, AKT1, APEX1, AR, AURKB, BLM, CSNK2A1, CTDSP1, DAPK1, DUSP3, EGFR, ESRRA, GSK3B, HIF1A, HSPA1A, IGF1R, KDR, PLK1, SMAD3, SRC, TP53, USP2, XDH |
BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 1.989E-04 | 8.929E-03 | AHR, EGFR, GSK3B, TP53, USP2 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.987E-04 | 8.929E-03 | IGF1R, INSR, PDGFRB |
BP | GO:0065007; biological regulation | GO:0051336; regulation of hydrolase activity | 2.017E-04 | 9.039E-03 | AKT1, CSNK2A1, DAPK1, EGFR, ERBB2, GSK3B, HSPA1A, NUAK1, PDGFRB, PTK2, SMAD3, SRC, TP53, XDH |
BP | GO:0009987; cellular process | GO:0071383; cellular response to steroid hormone stimulus | 2.067E-04 | 9.184E-03 | AR, EGFR, FLT3, SRC |
BP | GO:0009987; cellular process | GO:1901991; negative regulation of mitotic cell cycle phase transition | 2.131E-04 | 9.411E-03 | AURKA, AURKB, BLM, CTDSP1, PLK1, TP53 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.268E-04 | 9.879E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 2.268E-04 | 9.879E-03 | AURKA, AURKB |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.796E-19 | 2.960E-15 | CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.072E-15 | 2.122E-12 | CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9, HBB |
MF | GO:0005488; binding | GO:0005524; ATP binding | 9.807E-15 | 1.124E-11 | ABCC1, ABCG2, AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, DAPK1, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, NUAK1, PDGFRB, PLK1, PLK4, PTK2, RECQL, SRC, TEK, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.400E-18 | 3.889E-16 | CA12; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.124E-11 | 1.147E-09 | PDGFRB; GSK3B; SMAD3; FLT3; DAPK1; BRAF; HIF1A; EGFR; PTK2; IGF1R; AR; ERBB2; AKT1; MET; TP53 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.430E-11 | 1.147E-09 | PDGFRB; GSK3B; SRC; FLT4; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.049E-11 | 2.045E-09 | PDGFRB; GSK3B; AR; ERBB2; AKT1; BRAF; TP53; EGFR; IGF1R |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.891E-10 | 7.805E-09 | SRC; ERBB2; KDR; AKT1; BRAF; TP53; HIF1A; MET; PTK2; EGFR; IGF1R |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.622E-10 | 5.256E-09 | PDGFRB; FLT3; ERBB2; AKT1; TP53; MET; HIF1A; EGFR |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.364E-10 | 8.836E-09 | PDGFRB; SRC; INSR; FLT4; KDR; AKT1; BRAF; TEK; MET; EGFR; IGF1R |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.670E-10 | 8.494E-09 | SMAD3; CSNK2A1; SRC; INSR; ERBB2; MET; EGFR; IGF1R |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.558E-10 | 1.360E-08 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.806E-09 | 9.406E-08 | PDGFRB; GSK3B; INSR; FLT4; KDR; AKT1; TEK; TP53; MET; PTK2; EGFR; IGF1R |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 9.443E-09 | 1.345E-07 | PDGFRB; AKT1; BRAF; TP53; MET; EGFR; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.953E-08 | 4.617E-07 | GSK3B; SRC; ERBB2; AKT1; BRAF; EGFR; PTK2 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.990E-08 | 4.617E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; BRAF; EGFR; IGF1R |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.962E-09 | 1.345E-07 | DAPK1; SRC; ERBB2; BRAF; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.364E-08 | 4.713E-07 | GSK3B; ERBB2; AKT1; BRAF; TP53; EGFR |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.965E-07 | 1.516E-06 | PDGFRB; INSR; FLT4; KDR; AKT1; TEK; MET; EGFR; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.703E-07 | 1.452E-06 | PDGFRB; AKT1; BRAF; TP53; EGFR; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.277E-07 | 1.149E-06 | INSR; ERBB2; AKT1; TEK; HIF1A; EGFR; IGF1R |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.868E-07 | 1.513E-06 | SMAD3; ERBB2; AKT1; BRAF; TP53; EGFR |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 8.522E-08 | 8.121E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.584E-06 | 3.619E-05 | PDGFRB; DUSP3; AKT1; BRAF; MAP3K8; TP53; EGFR; HSPA1A |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.277E-06 | 1.604E-05 | ERBB2; AKT1; BRAF; TP53; EGFR |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.860E-07 | 5.051E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.789E-06 | 2.558E-05 | GSK3B; SMAD3; AKT1; BRAF; TP53 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 5.752E-05 | 3.328E-04 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.667E-08 | 7.763E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.514E-06 | 5.108E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.424E-06 | 4.625E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 6.342E-05 | 3.543E-04 | HPGD; FLT3; TP53; MET; PTK2; IGF1R |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.777E-05 | 3.660E-04 | CYP2C9; ALOX5; ALOX15; BRAF; CYP2C19 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.684E-05 | 4.396E-04 | GSK3B; SRC; AKT1; TP53; HIF1A |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.351E-04 | 5.876E-04 | PDGFRB; ABCC1; ERBB2; CYP1B1; TP53; MET; EGFR |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.103E-04 | 7.922E-04 | GAA; ALOX15; AKR1B1; CYP2C19; CYP3A4; TYR; HSD17B10; CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 8.526E-05 | 4.396E-04 | SRC; KDR; AKT1; PTK2 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.694E-04 | 6.627E-04 | GSK3B; CSNK2A1; AKT1; TP53; HSPA1A |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.526E-04 | 6.181E-04 | GSK3B; AKT1; BRAF; TP53; EGFR |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.029E-04 | 4.904E-04 | INSR; AKT1; HSPA1A; IGF1R |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 4.468E-04 | 1.632E-03 | PDGFRB; POLB; GSK3B; SMAD3; AKT1; TP53 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.088E-05 | 4.461E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.161E-04 | 5.223E-04 | AKT1; BRAF; MET; HIF1A |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 5.146E-04 | 1.774E-03 | PDGFRB; FLT3; FLT4; KDR; MET; EGFR |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.093E-04 | 5.061E-04 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.718E-04 | 6.627E-04 | SMAD3; AKT1; BRAF; TP53 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.532E-04 | 1.632E-03 | INSR; AKT1; TP53; IGF1R |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.380E-04 | 5.876E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.034E-03 | 3.220E-03 | GSK3B; CSNK2A1; AKT1; TP53; HSPA1A |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.308E-04 | 1.791E-03 | PLK1; AKT1; BRAF; IGF1R |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 7.314E-04 | 2.323E-03 | GSK3B; SRC; AKT1; BRAF; PTK2 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.515E-04 | 1.823E-03 | SRC; AKT1; EGFR; HSPA1A |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.948E-04 | 1.927E-03 | PDGFRB; AKT1; HIF1A; EGFR |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.335E-03 | 3.795E-03 | PDGFRB; SRC; BRAF; PTK2; EGFR |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.133E-03 | 3.464E-03 | GSK3B; AKT1; BRAF; TP53 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.242E-03 | 3.726E-03 | AR; PLK1; AURKA; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.280E-03 | 3.769E-03 | GSK3B; SMAD3; PLK1; TP53 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.398E-03 | 3.904E-03 | GSK3B; MET; PTK2; EPHB4 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.104E-03 | 5.497E-03 | GSK3B; SMAD3; AKT1; IGF1R |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.104E-03 | 5.497E-03 | GSK3B; SMAD3; CSNK2A1; TP53 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.946E-03 | 5.255E-03 | GSK3B; INSR; AKT1; BRAF |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.327E-03 | 5.800E-03 | SMAD3; SRC; AKT1; TP53 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.213E-03 | 5.603E-03 | PDGFRB; INSR; AKT1; EGFR |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 8.297E-03 | 1.792E-02 | GSK3B; INSR; AKT1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.627E-02 | 3.176E-02 | LMNA; AKT1; TP53 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.295E-03 | 1.597E-02 | GSK3B; AKT1; MAP3K8 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.030E-02 | 2.195E-02 | ALOX5; AKT1; HSPA1A |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.177E-02 | 2.445E-02 | INSR; AKT1; IGF1R |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.078E-02 | 2.267E-02 | ABCC1; AKT1; TP53 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.986E-02 | 3.740E-02 | GSK3B; INSR; AKT1 |
hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.597E-02 | 3.155E-02 | CSNK2A1; SRC; AKT1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.618E-02 | 4.820E-02 | BACE1; GSK3B; HSD17B10 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.304E-03 | 1.011E-02 | AKT1; TP53; PTK2 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 4.590E-03 | 1.062E-02 | PDGFRB; SRC; EGFR |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.605E-03 | 6.395E-03 | GSK3B; SRC; AKT1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.331E-03 | 3.795E-03 | FLT3; AKT1; BRAF |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.544E-03 | 4.241E-03 | AKT1; BRAF; HIF1A |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 3.270E-03 | 7.906E-03 | SRC; MET; PTK2 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.213E-03 | 5.603E-03 | SRC; MET; EGFR |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.709E-04 | 1.658E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.188E-02 | 4.075E-02 | BRAF; IGF1R |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.922E-02 | 3.664E-02 | INSR; AKT1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.858E-02 | 3.584E-02 | GSK3B; TP53 |
hsa05144 | Malaria_Homo sapiens_hsa05144 | 1.493E-02 | 2.987E-02 | HBB; MET |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.324E-02 | 2.681E-02 | CYP3A4; XDH |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.216E-02 | 2.494E-02 | ABCC1; ABCG2 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.414E-03 | 1.235E-02 | BRAF; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.786E-03 | 1.302E-02 | GAA; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 6.972E-03 | 1.547E-02 | POLB; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.424E-03 | 8.156E-03 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.415E-04 | 5.876E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | FLT4; MET; KDR; IGF1R |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; GSK3B |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
C00-D49: Neoplasms | AML | NA | KDR; FLT3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PLK1; AURKA |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR; ERBB2; EGFR; EGFR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; KDR; FLT3; ERBB2; EGFR; EGFR; IGF1R |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; SRC; AURKB |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR |
C00-D49: Neoplasms | Melanoma | C43 | BRAF; KDR; KDR; EGFR; TYR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
NA: NA | HIV infections | NA | AHR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; AKT1; INSR; CA9; ERBB2; EGFR; PLK1 |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1; TYR; ESRRA |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | BRAF; TP53; PTK2; AURKA |
C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; KDR; KDR; EGFR; EGFR; EGFR; AKR1B1 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; ERBB2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; AR |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; FLT3; ERBB2; EGFR; AR; AR; PLK1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; AR |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
C00-D49: Neoplasms | CLL | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PDGFRB; MET; KDR; EGFR; EGFR; IGF1R; IGF1R |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; ESRRA |
NA: NA | Male hypogonadism | NA | AR |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR |
C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; AHR; IGF1R |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ERBB2; ESRRA |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR; EGFR; EGFR |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; KDR; FLT3; EGFR; PLK1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; AR; IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | BRAF |
C00-D49: Neoplasms | Bladder cancer | C67 | ERBB2; EGFR; AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PDGFRB; INSR; AKR1B1; GSK3B |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; TEK; ABCC1; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
C00-D49: Neoplasms | Breast cancer | C50 | INSR; KDR; KDR; KDR; FLT3; FLT3; CA9; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; AR; IGF1R |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Cancer | C00-C96 | BRAF; BRAF; FLT4; TEK; HIF1A; AKT1; TP53; MET; KDR; SRC; FLT3; FLT3; CA9; ERBB2; ERBB2; EGFR; AR; EPHB4; PLK1; GSK3B; IGF1R; PTK2; AURKA; CSNK2A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; PLK1; AURKB; AURKA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT4; TEK; PDGFRB; HIF1A; AKT1; TP53; MET; KDR; KDR; KDR; SRC; FLT3; CA9; ERBB2; EGFR; PLK1; PLK1; IGF1R; PTK2; AURKB; AURKA |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |